Neutropenia as an Adverse Event following Vaccination: Results from Randomized Clinical Trials in Healthy Adults and Systematic Review

• Published in: PloS one Vol. 11; no. 8; p. e0157385
• Main Authors: Muturi-Kioi, Vincent, Lewis, David, Launay, Odile, Leroux-Roels, Geert, Anemona, Alessandra, Loulergue, Pierre, Bodinham, Caroline L, Aerssens, Annelies, Groth, Nicola, Saul, Allan, Podda, Audino
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 04-08-2016; Public Library of Science (PLoS)
• Subjects: Adults; Analysis; Benign; Biology and Life Sciences; Chicken pox; Clinical trials; Complications and side effects; Databases, Factual; Developmental stages; Dysentery, Bacillary - prevention & control; Encephalitis; Hematologic Tests; Hematology; Humans; Infectious diseases; Laboratories; Leukocytes (neutrophilic); Literature reviews; Medical research; Medicine and Health Sciences; Minority & ethnic groups; Neutropenia; Neutropenia - etiology; Neutropenia - pathology; Neutrophils; Pediatrics; Proteins; Randomized Controlled Trials as Topic; Research and analysis methods; Risk factors; Safety; Severity of Illness Index; Shigella; Shigella sonnei - immunology; Shigella Vaccines - adverse effects; Shigella Vaccines - immunology; Vaccination; Vaccines; Vaccines - adverse effects; Viruses; France; Italy; United Kingdom > UK; Belgium
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0157385

In the context of early vaccine trials aimed at evaluating the safety profile of novel vaccines, abnormal haematological values, such as neutropenia, are often reported. It is therefore important to evaluate how these trials should be planned not to miss potentially important safety signals, but also to understand the implications and the clinical relevance.
We report and discuss the results from five clinical trials (two with a new Shigella vaccine in the early stage of clinical development and three with licensed vaccines) where the absolute neutrophil counts (ANC) were evaluated before and after vaccination. Additionally, we have performed a systematic review of the literature on cases of neutropenia reported during vaccine trials to discuss our results in a more general context.
Both in our clinical trials and in the literature review, several cases of neutropenia have been reported, in the first two weeks after vaccination. However, neutropenia was generally transient and had a benign clinical outcome, after vaccination with either multiple novel candidates or well-known licensed vaccines. Additionally, the vaccine recipients with neutropenia frequently had lower baseline ANC than non-neutropenic vaccinees. In many instances neutropenia occurred in subjects of African descent, known to have lower ANC compared to western populations.
It is important to include ANC and other haematological tests in early vaccine trials to identify potential safety signals. Post-vaccination neutropenia is not uncommon, generally transient and clinically benign, but many vaccine trials do not have a sampling schedule that allows its detection. Given ethnic variability in the level of circulating neutrophils, normal ranges taking into account ethnicity should be used for determination of trial inclusion/exclusion criteria and classification of neutropenia related adverse events.
ClinicalTrials.gov NCT02017899, NCT02034500, NCT01771367, NCT01765413, NCT02523287.